Remicade Related Published Studies
Well-designed clinical trials related to Remicade (Infliximab)
Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). [2011.11]
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. [2011.09]
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. [2011.07]
Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. [2011.04]
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. [2011.03]
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. [2011.03]
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2011.02]
Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. [2011.01]
Early mucosal healing with infliximab is associated with improved long-term
clinical outcomes in ulcerative colitis. [2011]
Randomised clinical trial: improvement in health outcomes with certolizumab pegol
in patients with active Crohn's disease with prior loss of response to
infliximab. [2011]
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2010.12.07]
Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. [2010.12]
Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. [2010.12]
Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. [2010.10]
Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. [2010.10]
Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. [2010.10]
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. [2010.09.07]
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. [2010.09]
Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. [2010.08.01]
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. [2010.08]
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. [2010.08]
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. [2010.07]
Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. [2010.07]
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. [2010.06]
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). [2010.05]
Infliximab, azathioprine, or combination therapy for Crohn's disease. [2010.04.15]
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. [2010.04]
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. [2010.04]
[Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis]. [2010.04]
Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. [2010.03]
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. [2010.02]
Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. [2010.02]
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. [2010.02]
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. [2010]
C-reactive protein predicts response to infliximab in patients with chronic
sarcoidosis. [2010]
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque
psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled
multicenter trial. [2010]
Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on
magnetic resonance imaging in patients with ankylosing spondylitis: a randomized
placebo-controlled study. [2010]
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics
and clinical response in patients with ulcerative colitis. [2010]
Infliximab for diabetic macular edema refractory to laser photocoagulation: a
randomized, double-blind, placebo-controlled, crossover, 32-week study. [2010]
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing
spondylitis. [2010]
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa:
a randomized, double-blind, placebo-controlled crossover trial. [2010]
A placebo-controlled, double-blind trial of infliximab for cancer-associated
weight loss in elderly and/or poor performance non-small cell lung cancer
patients (N01C9). [2010]
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. [2009.12]
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. [2009.12]
Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. [2009.12]
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. [2009.12]
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. [2009.10]
Cost-effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomized controled trial. [2009.09.09]
A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. [2009.09]
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. [2009.08.15]
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. [2009.08.08]
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. [2009.08]
Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. [2009.08]
Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. [2009.08]
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. [2009.08]
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: A Belgian case series. [2009.07.27]
Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. [2009.07.15]
Efficacy and safety of infliximab in active SLE: a pilot study. [2009.07]
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. [2009.07]
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. [2009.06]
Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. [2009.05.15]
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. [2009.04]
Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. [2009.03]
Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. [2009.03]
Infliximab prevents Crohn's disease recurrence after ileal resection. [2009.02]
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. [2009.02]
Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. [2009]
Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial. [2008.12.25]
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. [2008.12]
Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. [2008.12]
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. [2008.10.15]
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. [2008.10]
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. [2008.09.15]
Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. [2008.09]
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. [2008.09]
Patterns of infliximab use among Crohn's disease patients in a community setting. [2008.09]
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). [2008.08.22]
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2008.08]
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. [2008.06]
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. [2008.06]
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. [2008.06]
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). [2008.05]
A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. [2008.05]
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. [2008.04]
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. [2008.03]
Efficacy of Infliximab in Extrapulmonary Sarcoidosis: Results from a Randomized Trial. [2008.02.06]
A review of infliximab use in ulcerative colitis. [2008.02]
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. [2008.02]
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. [2008.01]
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2008.01]
Effect of infliximab on the levels of TNF-alpha and TGF-beta in the whole blood cultures of irradiated patients. [2008]
Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. [2008]
Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2007.12.28]
Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2007.11.29]
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. [2007.10.08]
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. [2007.09]
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. [2007.09]
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. [2007.09]
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. [2007.09]
|
